PE20151180A1 - Anticuerpos anti-ceacam5 y usos de estos - Google Patents

Anticuerpos anti-ceacam5 y usos de estos

Info

Publication number
PE20151180A1
PE20151180A1 PE2015000631A PE2015000631A PE20151180A1 PE 20151180 A1 PE20151180 A1 PE 20151180A1 PE 2015000631 A PE2015000631 A PE 2015000631A PE 2015000631 A PE2015000631 A PE 2015000631A PE 20151180 A1 PE20151180 A1 PE 20151180A1
Authority
PE
Peru
Prior art keywords
antibodies
immunoconjugates
describes
ceacam5 antibodies
vectors
Prior art date
Application number
PE2015000631A
Other languages
English (en)
Spanish (es)
Inventor
Pierre-Francois Berne
Francis Blanche
Herve Bouchard
Beatrice Cameron
Tarik Dabdoubi
Stephanie Decary
Paul Ferrari
Alexey Rak
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20151180A1 publication Critical patent/PE20151180A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2015000631A 2012-11-20 2013-11-20 Anticuerpos anti-ceacam5 y usos de estos PE20151180A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12306444 2012-11-20

Publications (1)

Publication Number Publication Date
PE20151180A1 true PE20151180A1 (es) 2015-08-12

Family

ID=47257727

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000631A PE20151180A1 (es) 2012-11-20 2013-11-20 Anticuerpos anti-ceacam5 y usos de estos

Country Status (38)

Country Link
US (4) US9617345B2 (OSRAM)
EP (3) EP2922875B1 (OSRAM)
JP (1) JP6324399B2 (OSRAM)
KR (4) KR20240063172A (OSRAM)
CN (2) CN109180815B (OSRAM)
AR (1) AR093557A1 (OSRAM)
AU (2) AU2013349733C1 (OSRAM)
BR (1) BR112015010993B1 (OSRAM)
CA (2) CA2889962C (OSRAM)
CL (1) CL2015001321A1 (OSRAM)
CR (1) CR20150258A (OSRAM)
CY (1) CY1119219T1 (OSRAM)
DK (2) DK3199552T3 (OSRAM)
DO (1) DOP2015000110A (OSRAM)
EA (1) EA039377B1 (OSRAM)
EC (1) ECSP15025845A (OSRAM)
ES (2) ES2625742T3 (OSRAM)
HR (2) HRP20170743T1 (OSRAM)
HU (1) HUE033369T2 (OSRAM)
IL (1) IL238559B (OSRAM)
LT (2) LT2922875T (OSRAM)
MA (1) MA38194B1 (OSRAM)
MX (1) MX358321B (OSRAM)
MY (1) MY171100A (OSRAM)
NZ (1) NZ708528A (OSRAM)
PE (1) PE20151180A1 (OSRAM)
PH (1) PH12015501092B1 (OSRAM)
PL (2) PL3199552T3 (OSRAM)
PT (2) PT2922875T (OSRAM)
RS (2) RS55987B1 (OSRAM)
SG (1) SG11201503285TA (OSRAM)
SI (2) SI2922875T1 (OSRAM)
TN (1) TN2015000177A1 (OSRAM)
TW (2) TWI664192B (OSRAM)
UA (1) UA120247C2 (OSRAM)
UY (1) UY35147A (OSRAM)
WO (1) WO2014079886A1 (OSRAM)
ZA (1) ZA201502959B (OSRAM)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2889962C (en) 2012-11-20 2023-10-24 Sanofi Anti-ceacam5 antibodies and uses thereof
US9753036B2 (en) * 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
CN109147874A (zh) * 2014-09-02 2019-01-04 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
MA43025A (fr) 2015-10-02 2021-05-26 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3
AU2017205089B2 (en) 2016-01-08 2023-10-05 F. Hoffmann-La Roche Ag Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
EP3523333B1 (en) * 2016-10-10 2023-12-13 Singapore Health Services Pte Ltd Anti-ceacam6 antibodies and methods of use
EP3543337B1 (en) 2016-11-18 2022-04-20 Astellas Pharma Inc. Novel anti-human muc1 antibody fab fragment
CN111533805B (zh) * 2016-12-04 2022-02-08 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的高亲和力纳米抗体及其应用
CN108341876B (zh) * 2017-01-22 2021-06-04 中国人民解放军第四军医大学 抗人ceacam5单克隆抗体及其制备方法和应用
CN106946989B (zh) * 2017-03-02 2020-02-18 深圳市国创纳米抗体技术有限公司 抗cea抗原vhh结构域及含有其的双特异性抗体
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CA3069363A1 (en) * 2017-07-11 2019-01-17 Pfizer Inc. Immunogenic compositions comprising cea muc1 and tert
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
KR20200131840A (ko) 2018-03-13 2020-11-24 자임워크스 인코포레이티드 항-her2 2파라토프 항체-약물 접합체 및 이의 사용 방법
CA3096222A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
WO2019204827A2 (en) * 2018-04-20 2019-10-24 The Regents Of The University Of California Treatment of prostate cancer using chimeric antigen receptors
WO2019221269A1 (ja) 2018-05-17 2019-11-21 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
US11555071B2 (en) 2018-06-03 2023-01-17 Lamkap Bio Beta Ltd. Bispecific antibodies against CEACAM5 and CD47
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
CN110684108B (zh) * 2018-07-06 2021-06-04 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(CEA37)及其用途
CN110684107B (zh) * 2018-07-06 2021-03-23 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(MGd1)及其用途
EP4592314A3 (en) 2018-08-30 2025-11-05 ImmunityBio, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
WO2020047333A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
SG11202101779RA (en) 2018-08-30 2021-03-30 Hcw Biologics Inc Multi-chain chimeric polypeptides and uses thereof
CN112839683B (zh) * 2018-10-10 2023-11-14 安斯泰来制药株式会社 含有标记部-抗人抗体Fab片段复合物的药物组合物
CN111487411B (zh) * 2019-01-29 2023-05-09 瑞博奥(广州)生物科技股份有限公司 Ceacam1多肽的新应用
KR20210124260A (ko) * 2019-02-07 2021-10-14 사노피 폐암을 치료하기 위한 항-ceacam5 면역접합체의 용도
EP3693023A1 (en) 2019-02-11 2020-08-12 Sanofi Use of anti-ceacam5 immunoconjugates for treating lung cancer
CN114286690A (zh) * 2019-04-23 2022-04-05 赛诺菲 稳定的低粘度抗体配制品及其用途
TWI844684B (zh) * 2019-06-04 2024-06-11 大陸商普米斯生物技術（珠海）有限公司 一種抗ceacam5的單殖株抗體及其製備方法和用途
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
AU2020291014B2 (en) 2019-06-13 2025-06-05 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
CN114269903B (zh) 2019-06-21 2025-11-25 免疫生物公司 多链嵌合多肽和其用途
JP7354306B2 (ja) 2019-06-27 2023-10-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規ｉｃｏｓ抗体及びそれらを含む腫瘍標的化抗原結合分子
EP4025254A1 (en) 2019-09-03 2022-07-13 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
KR20220113353A (ko) 2019-09-18 2022-08-12 람캅 바이오 알파 에이지 Ceacam5 및 cd3에 대한 이중특이적 항체
EP4038053A1 (en) 2019-09-30 2022-08-10 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
US11807687B2 (en) 2019-10-03 2023-11-07 Atyr Pharma, Inc. Therapeutic compositions comprising anti-NRP2 antibodies
CA3155077A1 (en) 2019-10-25 2021-04-29 Romas Kudirka Thienoazepine immunoconjugates, and uses thereof
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
AU2021219720B2 (en) 2020-02-11 2025-10-02 Immunitybio, Inc. Chromatography resin and uses thereof
AU2021220870A1 (en) 2020-02-11 2022-08-04 Immunitybio, Inc. Methods of treating age-related and inflammatory diseases
KR20220140572A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 조절 t 세포를 활성화시키는 방법
CN115427082A (zh) * 2020-04-24 2022-12-02 赛诺菲 含有抗ceacam5抗体缀合物和folfox的抗肿瘤组合
IL297207A (en) * 2020-04-24 2022-12-01 Sanofi Sa Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
US20230087871A1 (en) 2020-04-24 2023-03-23 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
CA3180872A1 (en) * 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab
US12497462B2 (en) 2020-04-29 2025-12-16 Immunitybio, Inc. Anti-CD26 proteins and uses thereof
WO2021226440A1 (en) 2020-05-08 2021-11-11 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
WO2021247003A1 (en) 2020-06-01 2021-12-09 HCW Biologics, Inc. Methods of treating aging-related disorders
KR20230031280A (ko) 2020-06-01 2023-03-07 에이치씨더블유 바이올로직스, 인크. 노화 관련 장애의 치료 방법
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
CN111690061B (zh) * 2020-06-28 2022-08-23 中国人民解放军东部战区疾病预防控制中心 人源化抗鼠疫耶尔森菌抗原f1的抗体及应用
CN113234164B (zh) * 2020-08-04 2022-04-01 中山大学附属第五医院 抗ceacam5纳米抗体
MX2023001679A (es) 2020-08-13 2023-02-22 Bolt Biotherapeutics Inc Inmunoconjugados de pirazolazepina y usos de estos.
EP4100028A4 (en) 2020-08-20 2023-07-26 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF MESOTHELIN-POSITIVE CARCINOMAS
MX2023002017A (es) 2020-08-20 2023-04-28 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para ceacam.
AU2021335257A1 (en) * 2020-09-04 2023-03-09 Merck Patent Gmbh Anti-CEACAM5 antibodies and conjugates and uses thereof
US20220202946A1 (en) * 2020-11-10 2022-06-30 Sanofi Ceacam5 antibody-drug conjugate formulation
WO2022116079A1 (zh) * 2020-12-03 2022-06-09 上海吉倍生物技术有限公司 一种抗ceacam5的人源化抗体及其制备方法和用途
CA3200051A1 (en) 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Anti-cea immunoconjugates, and uses thereof
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
JP2024505333A (ja) 2020-12-21 2024-02-06 フリーノム ホールディングス，インク． 結腸細胞増殖障害の早期検出のためのマーカー
CN112521509B (zh) * 2020-12-23 2022-07-08 姚雪英 一种抗ceacam5人源化抗体、其缀合物及其用途
JP2024513313A (ja) * 2021-03-08 2024-03-25 ユニバーシティ オブ ピッツバーグ －オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション ＣＤ６６ｅポリペプチドに結合する分子
CA3212926A1 (en) 2021-03-26 2022-09-29 Gary Brandt 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
AU2022245340A1 (en) 2021-03-26 2023-11-09 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
JP2024519078A (ja) * 2021-05-21 2024-05-08 ベイジーン スウィッツァーランド ゲーエムベーハー 抗ｃｅａ抗体及びその使用方法
WO2023057564A1 (en) 2021-10-07 2023-04-13 Sanofi IMIDAZO[4,5-c]QUINOLINE-4-AMINE COMPOUNDS AND CONJUGATES THEREOF, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATIONS
TW202333797A (zh) 2021-11-05 2023-09-01 法商賽諾菲公司 含有抗ceacam5抗體-藥物接合物及抗vegfr-2抗體之抗腫瘤組合
JP2024540374A (ja) * 2021-11-05 2024-10-31 アメリカン ダイアグノスティックス アンド セラピー， エルエルシー （エーディーエックスアールエックス） がん胎児性抗原に対するモノクローナル抗体、及びそれらの使用
TW202340241A (zh) 2021-12-02 2023-10-16 法商賽諾菲公司 Ｃｅａｃａｍ５ ａｄｃ－抗ｐｄ１／ｐｄ－ｌ１組合療法
JP2024545428A (ja) 2021-12-02 2024-12-06 サノフイ 癌治療における患者選択のためのｃｅａアッセイ
US20250188170A1 (en) * 2022-02-25 2025-06-12 Atyr Pharma, Inc. COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2b ANTIBODIES
EP4486368A1 (en) 2022-03-02 2025-01-08 ImmunityBio, Inc. Method of treating pancreatic cancer
CA3254105A1 (en) * 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-CEACAM5 antibodies and their conjugates and their uses
AU2023237620A1 (en) 2022-03-23 2024-08-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
JP2025527967A (ja) 2022-08-10 2025-08-26 メルク・シャープ・アンド・ドーム・エルエルシー タンパク質結合ｎｋｇ２ｄ、ｃｄ１６、及びｃｅａｃａｍ５
EP4642810A1 (en) * 2022-12-28 2025-11-05 Full-Life Technologies HK Limited Antibodies specifically binding to ceacam5
TW202502387A (zh) 2023-03-01 2025-01-16 法商賽諾菲公司 抗ceacam5免疫接合物用於治療表現ceacam5的神經內分泌癌症之用途
EP4427763A1 (en) 2023-03-06 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
WO2024250924A1 (en) * 2023-06-05 2024-12-12 Nona Biosciences (Suzhou) Co., Ltd. Anti-ceacam5/6 dual-binding antibodies
TW202513094A (zh) 2023-06-05 2025-04-01 法商賽諾菲公司 含有抗ceacam5抗體藥物接合物、抗pd1/pd-l1抗體及抗ctla4抗體之抗腫瘤組合
WO2025031923A1 (en) 2023-08-04 2025-02-13 Sanofi Imidazo[4,5-d]pyridazine compounds and conjugates thereof, their preparation, and their therapeutic applications
CN119978136A (zh) * 2023-11-10 2025-05-13 信达生物制药(苏州)有限公司 抗dr5和ceacam5的双特异性抗体及其用途
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025169012A1 (en) 2024-02-06 2025-08-14 Sanofi Methods of treating ceacam5-expressing cancers
WO2025184208A1 (en) * 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2025242098A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对ceacam5的抗体偶联药物及其用途

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US417A (en) 1837-09-28 Endless-ghain horse-power for driving iviaci-iii
US244A (en) 1837-06-30 Edward flint
US4670A (en) 1846-07-28 Improvement in fish-hooks
US4640A (en) 1846-07-14 Book-lock
US144A (en) 1837-03-11 Improvement in scythe-snaths
US835A (en) 1838-07-12 X i i i x
US5204A (en) 1847-07-24 james cantelo
US192A (en) 1837-05-15 Machine for cutting
US689A (en) 1838-04-13 Julius austin
US4301A (en) 1845-12-11 Ebenezbr barrows
US4496A (en) 1846-05-02 Machinery for
US4791A (en) 1846-10-03 john g
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
AU6248994A (en) 1993-02-22 1994-09-14 Rockefeller University, The Production of high titer helper-free retroviruses by transient transfection
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
EP0811691B1 (en) 1995-09-11 2004-12-01 Kyowa Hakko Kogyo Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1998045322A2 (en) 1997-04-10 1998-10-15 Royal Netherlands Academy Of Arts And Sciences Diagnosis method and reagents
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
CA2495795C (en) 2002-08-16 2011-12-13 Immunogen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
WO2004094613A2 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
PL1976880T3 (pl) 2005-12-21 2017-01-31 Amgen Research (Munich) Gmbh Kompozycje farmaceutyczne odporne na rozpuszczalny cea
ES2673822T3 (es) 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
CN106432496B (zh) 2007-07-16 2020-02-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
WO2009032661A1 (en) 2007-08-29 2009-03-12 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
KR101764927B1 (ko) 2008-04-30 2017-08-03 이뮤노젠 아이엔씨 가교제 및 그 용도
CN102482701B (zh) * 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
EP3333193A1 (en) * 2011-03-02 2018-06-13 Roche Glycart AG Cea antibodies
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
CA2889962C (en) 2012-11-20 2023-10-24 Sanofi Anti-ceacam5 antibodies and uses thereof
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
CN104948958A (zh) * 2015-07-01 2015-09-30 上海顿格电子贸易有限公司 一种利用热敏电阻限流的led灯
CN108341876B (zh) * 2017-01-22 2021-06-04 中国人民解放军第四军医大学 抗人ceacam5单克隆抗体及其制备方法和应用
EP3866924A4 (en) * 2018-06-29 2022-07-06 Krystal Biotech, Inc. COMPOSITIONS AND METHODS OF ANTIBODY DELIVERY
KR20210124260A (ko) * 2019-02-07 2021-10-14 사노피 폐암을 치료하기 위한 항-ceacam5 면역접합체의 용도
CA3180872A1 (en) * 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and cetuximab
IL297207A (en) * 2020-04-24 2022-12-01 Sanofi Sa Antitumor combinations containing anti-ceacam5 antibody conjugates, trifluridine and tipiracil
US20230087871A1 (en) * 2020-04-24 2023-03-23 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
US20220202946A1 (en) * 2020-11-10 2022-06-30 Sanofi Ceacam5 antibody-drug conjugate formulation
JP2024545428A (ja) * 2021-12-02 2024-12-06 サノフイ 癌治療における患者選択のためのｃｅａアッセイ
AU2023379743A1 (en) * 2022-11-17 2025-07-03 Sanofi Ceacam5 antibody-drug conjugates and methods of use thereof

Also Published As

Publication number Publication date
AU2013349733A1 (en) 2015-06-11
CN104918958B (zh) 2019-12-10
CL2015001321A1 (es) 2015-07-17
TN2015000177A1 (en) 2016-10-03
LT2922875T (lt) 2017-06-12
HK1215444A1 (en) 2016-08-26
JP2016506370A (ja) 2016-03-03
IL238559A0 (en) 2015-06-30
SI2922875T1 (sl) 2017-06-30
MY171100A (en) 2019-09-25
KR102194748B1 (ko) 2020-12-23
DK3199552T3 (da) 2020-03-30
HRP20200415T1 (hr) 2020-06-26
KR102661801B1 (ko) 2024-04-26
IL238559B (en) 2018-10-31
EP3199552B1 (en) 2019-12-25
RS60043B1 (sr) 2020-04-30
RS55987B1 (sr) 2017-09-29
UA120247C2 (uk) 2019-11-11
US9617345B2 (en) 2017-04-11
BR112015010993B1 (pt) 2022-08-30
US20220340682A1 (en) 2022-10-27
KR20200143527A (ko) 2020-12-23
UY35147A (es) 2014-06-30
BR112015010993A2 (OSRAM) 2017-08-22
WO2014079886A1 (en) 2014-05-30
ECSP15025845A (es) 2016-01-29
HUE033369T2 (en) 2017-11-28
EP2922875B1 (en) 2017-03-15
PL3199552T3 (pl) 2020-06-01
EP2922875A1 (en) 2015-09-30
CA3207769A1 (en) 2014-05-30
CN109180815A (zh) 2019-01-11
CN109180815B (zh) 2022-06-21
AU2013349733B2 (en) 2018-08-23
EP3594243A1 (en) 2020-01-15
SI3199552T1 (sl) 2020-06-30
AU2013349733C1 (en) 2020-10-01
KR20220084193A (ko) 2022-06-21
CN104918958A (zh) 2015-09-16
DK2922875T3 (en) 2017-06-06
KR20150085828A (ko) 2015-07-24
US11332542B2 (en) 2022-05-17
PT2922875T (pt) 2017-05-31
PH12015501092A1 (en) 2015-07-27
EP3199552A1 (en) 2017-08-02
MA38194A1 (fr) 2018-02-28
ZA201502959B (en) 2016-01-27
TW201427997A (zh) 2014-07-16
KR102408660B1 (ko) 2022-06-15
ES2625742T3 (es) 2017-07-20
MX2015006374A (es) 2015-10-09
KR20240063172A (ko) 2024-05-09
NZ708528A (en) 2020-07-31
MA38194B1 (fr) 2018-12-31
PT3199552T (pt) 2020-03-25
AU2018267636A1 (en) 2018-12-13
HRP20170743T1 (hr) 2017-07-28
ES2778823T3 (es) 2020-08-12
EA201590986A1 (ru) 2016-05-31
PL2922875T3 (pl) 2017-08-31
US20180022817A1 (en) 2018-01-25
JP6324399B2 (ja) 2018-05-16
PH12015501092B1 (en) 2019-01-11
AR093557A1 (es) 2015-06-10
CR20150258A (es) 2015-06-11
EA039377B1 (ru) 2022-01-20
US10457739B2 (en) 2019-10-29
LT3199552T (lt) 2020-04-10
CA2889962C (en) 2023-10-24
SG11201503285TA (en) 2015-05-28
MX358321B (es) 2018-08-14
US20160108131A1 (en) 2016-04-21
CY1119219T1 (el) 2018-02-14
TW201940519A (zh) 2019-10-16
US20200102401A1 (en) 2020-04-02
TWI664192B (zh) 2019-07-01
CA2889962A1 (en) 2014-05-30
DOP2015000110A (es) 2015-08-16

Similar Documents

Publication Publication Date Title
PE20151180A1 (es) Anticuerpos anti-ceacam5 y usos de estos
CO2023004252A2 (es) Anticuerpos anti-ceacam5 y conjugados y usos de los mismos
CY1123355T1 (el) Αντισωματα εναντι cd73 και χρησεις εξ αυτων
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
BR112017025191A2 (pt) anticorpos contra ox40 e uso dos mesmos
MX2019009468A (es) Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer.
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
BR112017014258A2 (pt) anticorpos anti-cd47 e usos dos mesmos
UY35250A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos.
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica
NI201500002A (es) Agentes de unión de rspo3 y usos de los mismos.
EA201400625A1 (ru) Антитела против pd-l1 и их применение
MX390894B (es) Polipéptido de fusión anti-cáncer.
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
EA201790773A1 (ru) Композиции и способы для ингибирования биологической активности растворимых биомолекул
MX2016014826A (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
AR104484A1 (es) Anticuerpos anti-psma como agentes terapéuticos
AR123279A1 (es) Anticuerpos y conjugados anti-ceacam5 y usos de los mismos
BR112016030462A2 (pt) moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo

Legal Events

Date Code Title Description
FG Grant, registration